Recordati Industria Chimica e Farmaceutica Full Year 2024 Earnings: EPS: €2.02 (vs €1.89 in FY 2023)

Recordati Industria Chimica e Farmaceutica (BIT:REC) Full Year 2024 Results

Key Financial Results

• Revenue: €2.34b (up 12% from FY 2023).
• Net income: €416.5m (up 7.0% from FY 2023).
• Profit margin: 18% (in line with FY 2023).
• EPS: €2.02 (up from €1.89 in FY 2023).

REC Products In Clinical Trials

• Phase II: 1.

REC Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Recordati Industria Chimica e Farmaceutica Earnings Insights

The primary driver behind last 12 months revenue was the Specialty & Primary Care segment contributing a total revenue of €1.51b (64% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to €497.7m (41% of total expenses). Explore how REC's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Italy.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Recordati Industria Chimica e Farmaceutica, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.